ONO 4578

Drug Profile

ONO 4578

Alternative Names: BMS-986310

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 30 Aug 2018 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in Belgium, USA (PO) (NCT03661632)
  • 30 Aug 2018 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease) in Belgium, USA (PO) (NCT03661632)
  • 13 Dec 2017 ONO 4578 licensed to Bristol-Myers Squibb worldwide except Japan, South Korea, Taiwan, China and Association of Southeast Asian Nations countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top